Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Azopt
AZOPT 10 mg/ml eye drops, suspension · Abschnitt 4.5 · PDF-Seite 4–5
HOS-090573 · Präparat HOS-084087
4
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main),
CYP2A6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as ketoconazole,
itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of brinzolamide
by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly. However,
accumulation of brinzolamide is unlikely as renal elimination is the major route. Brinzolamide is not
an inhibitor of cytochrome P-450 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) clotrimazole (HOS-090574) itraconazole (HOS-084516) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-09T11:23:00Z · SHA-256 d0be850656f9509e71878bc85c7d0b4029d40e9296b4026f616ccfa56bd15b67 · Passage 1cb8578282141ccd7e7c5127a0661aba79ce86b7afac0f06741f560b1122da98 · Zeichen 693–1212 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Effentora
Effentora 100 micrograms buccal tablets Effentora 200 micrograms buccal tablets Effentora 400 micrograms buccal tablets Effentora 600 micrograms buccal tablets Effentora 800 micrograms buccal tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-209208 · Präparat HOS-154273
CYP3A4 inhibitors
The concomitant use of Effentora with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole,
itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e.g.,
amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T10:58:00Z · SHA-256 b4a304bd9d2ca3f423d95be522ff20307f46a2ce762379e94c21a56805a240f8 · Passage 0cf5c88c70c4ae39f0d76035db9f738e3de8f9e72008c3bf601dfee4d384ee76 · Zeichen 359–669 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7
HOS-120558 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms nasal spray, solution in single-dose container Instanyl 100 micrograms nasal spray, solution in single-dose container Instanyl 200 micrograms nasal spray, solution in single-dose container · Abschnitt 4.5 · PDF-Seite 20
HOS-120583 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Instanyl
Instanyl 50 micrograms/dose nasal spray, solution Instanyl 100 micrograms/dose nasal spray, solution Instanyl 200 micrograms/dose nasal spray, solution · Abschnitt 4.5 · PDF-Seite 33
HOS-120606 · Präparat HOS-095157
Fentanyl is metabolised mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4),
therefore potential interactions may occur when Instanyl is given concurrently with medicinal products
that affect CYP3A4 activity. Coadministration with medicinal products that induce 3A4 activity may
reduce the efficacy of Instanyl. The concomitant use of Instanyl with strong CYP3A4 inhibitors (e.g.
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g., amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
and verapamil) may result in increased fentanyl plasma concentrations, potentially causing serious
adverse drug reactions including fatal respiratory depression.
Patients receiving Instanyl concomitantly with moderate or strong CYP3A4 inhibitors should be
carefully monitored for an extended period of time. Dose increase should be done with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T14:16:00Z · SHA-256 c62f47d72fc641986d789e1b677e3be39ccd613b0c706fbcdbe36063f292309f · Passage 5c9d8fc4948ebac2552fc912d78e14775b0ca4461a94126b50e09135530da315 · Zeichen 644–1590 im Abschnitt
Wechselwirkungen · Azarga
AZARGA 10 mg/ml + 5 mg/ml eye drops, suspension · Abschnitt 4.5 · PDF-Seite 6
HOS-120632 · Präparat HOS-095177
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main),
CYP2A6, CYP2B6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as
ketoconazole, itraconazole, clotrimazole, ritonavir and troleandomycin will inhibit the metabolism of
brinzolamide by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly.
However, accumulation of brinzolamide is unlikely as renal elimination is the major route.
Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) clotrimazole (HOS-090574) itraconazole (HOS-084516) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T11:25:00Z · SHA-256 31d2d9680fb40d91c0814e4a11af0fd7afd46b076a9707025daaf594939f4a9e · Passage 2cbabca0a503edbfca13e55800dcff6df8fb142888aabfac4184f448b0529203 · Zeichen 682–1206 im Abschnitt
Wechselwirkungen · PecFent
PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution · Abschnitt 4.5 · PDF-Seite 7–8
HOS-212292 · Präparat HOS-154864
7
ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate
CYP3A4 inhibitors (e.g. amprenavir, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir,
grapefruit juice, and verapamil) may result in increased fentanyl plasma concentrations, potentially
causing serious adverse drug reactions including fatal respiratory depression. Patients receiving
PecFent concomitantly with moderate or strong CYP3A4 inhibitors should be carefully monitored for
an extended period of time. Dose increase should be undertaken with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nelfinavir (HOS-084520) ketoconazole (HOS-084513) aprepitant (HOS-112506) grapefruit juice (HOS-088787) itraconazole (HOS-084516) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) troleandomycin (HOS-090575) fosamprenavir (HOS-086182) ritonavir (HOS-084521) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-29T09:30:00Z · SHA-256 6c66e20c8a5497199e4a93d57ee169d120fab4ca07ded4b5af9add0ded3852e4 · Passage baea18cdc0d760a3126f0945c5f69a526986b9a3412eefdc3117a24e58041ab8 · Zeichen 656–1232 im Abschnitt
Wechselwirkungen · Iclusig
Iclusig 15 mg film-coated tablets Iclusig 30 mg film-coated tablets Iclusig 45 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-128502 · Präparat HOS-096579
Caution should be exercised and a reduction of the starting dose of Iclusig in adults to 30 mg should
be considered with concurrent use of strong CYP3A inhibitors such as clarithromycin, indinavir,
itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,
troleandomycin, voriconazole, and grapefruit juice.
For paediatric patients a reduction of the starting dose should be considered as described in section
4.2.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-31T14:12:00Z · SHA-256 4867aa10684948b4c421d8ab4cf806af86df3e9279763348c485fe3b6e3627c4 · Passage e077c53e74db26b42f33dac432109829009283944476cf4195e795d10fa77cf3 · Zeichen 444–890 im Abschnitt
Wechselwirkungen · Iclusig
Iclusig 5 mg hard capsules · Abschnitt 4.5 · PDF-Seite 56
HOS-128555 · Präparat HOS-096579
Caution should be exercised and a reduction of the starting dose of Iclusig in adults to 30 mg should
be considered with concurrent use of strong CYP3A inhibitors such as clarithromycin, indinavir,
itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin,
troleandomycin, voriconazole, and grapefruit juice.
For paediatric patients a reduction of the starting dose should be considered as described in section
4.2.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-31T14:12:00Z · SHA-256 4867aa10684948b4c421d8ab4cf806af86df3e9279763348c485fe3b6e3627c4 · Passage e077c53e74db26b42f33dac432109829009283944476cf4195e795d10fa77cf3 · Zeichen 500–946 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139158 · Präparat HOS-098290
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics (e.g., neurotoxicity, QT prolongation) is unavoidable, consider
telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, (see section 4.4). the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors (e.g., tacrolimus levels may occur, as tacrolimus the next day at a
ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase >5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with and tacrolimus exposure may increase needed based on tacrolimus
without dasabuvir), >50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, ceritinib. The effect on tacrolimus blood first few days) and re-
Strong interactions have also concentrations may remain for evaluated on and after
been observed with the several days after co-administration completion of the CYP3A4
macrolide antibiotic is completed. inhibitor. Upon completion,
erythromycin. appropriate dose and dosing
frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) (see section 4.4). A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed (see
azithromycin), calcium may occur. section 4.2). Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68eefd97f11d29951c1cb7e82fce1c09e7dec9a4f694ee7101cde8ef1e7bf3ae · Zeichen 3968–8645 im Abschnitt
Wechselwirkungen · Lorviqua
Lorviqua 25 mg film-coated tablets Lorviqua 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-140205 · Präparat HOS-098468
Itraconazole, a strong inhibitor of CYP3A4/5, administered at oral doses of 200 mg once daily for
5 days, increased the mean lorlatinib AUCinf by 42% and Cmax by 24% of a single 100 mg oral dose of
lorlatinib in healthy volunteers. Concomitant administration of lorlatinib with strong CYP3A4/5
inhibitors (e.g. boceprevir, cobicistat, itraconazole, ketoconazole, posaconazole, troleandomycin,
voriconazole, ritonavir, paritaprevir in combination with ritonavir and ombitasvir and/or dasabuvir,
and ritonavir in combination with either elvitegravir, indinavir, lopinavir or tipranavir) may increase
lorlatinib plasma concentrations. Grapefruit products may also increase lorlatinib plasma
concentrations and should be avoided. An alternative concomitant medicinal product with less
potential to inhibit CYP3A4/5 should be considered. If a strong CYP3A4/5 inhibitor must be
concomitantly administered, a dose reduction of lorlatinib is recommended (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) ketoconazole (HOS-084513) cobicistat (HOS-088111) dasabuvir (HOS-110302) voriconazole (HOS-084524) itraconazole (HOS-084516) ombitasvir (HOS-110300) boceprevir (HOS-090617) troleandomycin (HOS-090575) ritonavir (HOS-084521) paritaprevir (HOS-110301) posaconazole (HOS-085622) elvitegravir (HOS-088110) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-03T10:16:00Z · SHA-256 e78bfe12c86e5d234c5c39cb88b4ddb1774142065643260a485f8cad944b4467 · Passage e8879edd76b5e755e2fe1c01adb047528d6e641219dc730314c408fa86169585 · Zeichen 1328–2292 im Abschnitt
Wechselwirkungen · Scemblix
Scemblix 20 mg film-coated tablets Scemblix 40 mg film-coated tablets Scemblix 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-148088 · Präparat HOS-099834
Strong CYP3A4 inhibitors
Caution should be exercised during concomitant administration of asciminib at 200 mg twice daily
with strong CYP3A4 inhibitors, including, but not limited to, clarithromycin, telithromycin,
troleandomycin, itraconazole, ketoconazole, voriconazole, ritonavir, indinavir, nelfinavir or
saquinavir. Dose adjustment of asciminib is not required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nelfinavir (HOS-084520) ketoconazole (HOS-084513) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) troleandomycin (HOS-090575) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-07T15:31:00Z · SHA-256 a2fd46262678a8eeb46669611ee0714c6effd5303baddb16f404cbe6b0d0ab23 · Passage 9cb9746b09d01ee4bba697942015e35b0f69a852f694c8633dddfe05891f37b4 · Zeichen 595–961 im Abschnitt
Wechselwirkungen · Joenja
Joenja 70 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-150264 · Präparat HOS-100280
CYP3A4 inhibitors
Leniolisib is cleared primarily through oxidative metabolism (primarily hydroxylation and
dealkylation) by CYP isoenzymes (predominantly CYP3A4, 95.4%). In a study of healthy adults,
co-administration of leniolisib and itraconazole, a strong CYP3A4 inhibitor, resulted in a 2-fold
increase in leniolisib exposure. Concomitant use of leniolisib with strong CYP3A4 inhibitors (e.g.,
cobicistat, danoprevir, elvitegravir, indinavir, itraconazole, ketoconazole, lopinavir, ombitasvir,
paritaprevir, posaconazole, ritonavir, saquinavir, telithromycin, tipranavir, troleandomycin,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) ketoconazole (HOS-084513) cobicistat (HOS-088111) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) troleandomycin (HOS-090575) ritonavir (HOS-084521) paritaprevir (HOS-110301) posaconazole (HOS-085622) elvitegravir (HOS-088110) tipranavir (HOS-086184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-25T08:30:00Z · SHA-256 86ff542b4d3f7d0061b00035c52721373fd7e4b34a35a937a43304ec20dbf3fd · Passage f345486c56d7cd489f780034b9178f78b70dcd32fbab6464d6fb6af4379f844b · Zeichen 65–657 im Abschnitt
Wechselwirkungen · Truqap
TRUQAP 160 mg film-coated tablets TRUQAP 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150749 · Präparat HOS-100380
Strong CYP3A4 inhibitors
Co-administration of TRUQAP with strong CYP3A4 inhibitors increases capivasertib concentration,
which may increase the risk of TRUQAP toxicity. Co-administration with strong CYP3A4 inhibitors
should be avoided (e.g. boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, ensitrelvir,
idelalisib, indinavir, itraconazole, josamycin, ketoconazole, lonafarnib, mibefradil, mifepristone,
nefazodone, nelfinavir, posaconazole, ribociclib, ritonavir, saquinavir, telaprevir, telithromycin,
troleandomycin, tucatinib, voriconazole, grapefruit or grapefruit juice). If co-administration cannot be
avoided, TRUQAP dose should be reduced (see section 4.2). Co-administration of multiple 200 mg
doses of the strong CYP3A4 inhibitor itraconazole increased capivasertib total exposure (AUCinf) and
the peak concentration (Cmax) by 95% and 70%, respectively, relative to capivasertib given alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) ensitrelvir (HOS-150750) nelfinavir (HOS-084520) lonafarnib (HOS-150752) ketoconazole (HOS-084513) cobicistat (HOS-088111) conivaptan (HOS-128737) mibefradil (HOS-125440) grapefruit juice (HOS-088787) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ribociclib (HOS-109454) troleandomycin (HOS-090575) ritonavir (HOS-084521) mifepristone (HOS-150754) tucatinib (HOS-145562) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T12:20:00Z · SHA-256 b060cde010dec5d14aa99becadb87be90da15add7354e09540675f70797404c4 · Passage 9d76d32723b655988bd3a6c4736cb8a295aefc0434f36712e4bb18a737a08b2f · Zeichen 210–1125 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.